Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies for patients with autoimmune diseases [2] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to inhibit the activity of B cells implicated in autoimmune diseases without depleting them [2] Upcoming Events - Zenas will participate in several healthcare investor conferences, including: - Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA - Jefferies London Healthcare Conference on November 19, 2024, with a presentation scheduled from 4:00 p.m. to 4:25 p.m. [1] - Citi's 2024 Global Healthcare Conference on December 3, 2024, with a presentation from 9:30 a.m. to 10:10 a.m. ET in Miami, FL [1] - Evercore ISI HealthCONx Conference on December 4, 2024, with a presentation from 1:20 p.m. to 1:40 p.m. ET in Coral Gables, FL [1] - Live webcasts and archived replays of the presentations will be available on the Zenas BioPharma website [1]
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences